CRISPR Therapeutics Stock Price - CRSP

-0.4345 (-0.88%)
Upgrade to Real-Time
Regular Market
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
CRISPR Therapeutics AG CRSP NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-0.4345 -0.88% 49.0055 47.00 49.9974 47.52 49.44 11:07:14
Bid Price Ask Price Spread Spread % News
48.97 49.09 0.12 0.24% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
4,901 479,547 $ 48.61 $ 23,308,419 1,092,906 33.55 - 74.48
Last Trade Time Type Quantity Stock Price Currency
11:06:38 200 $ 49.0055 USD

CRISPR Therapeutics Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 2.98B 60.85M $ -164.98M 0.98 57.90 59.98M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

CRISPR Therapeutics News

Loading Messages....

Latest CRSP Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CRSP Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week56.6957.068247.0051.041,121,956-7.68-13.56%
1 Month52.4461.9047.0054.631,125,202-3.43-6.55%
3 Months71.4873.607747.0059.301,051,872-22.47-31.44%
6 Months44.5074.4835.4657.29929,5544.5110.12%
1 Year36.8574.4833.5551.64754,08112.1632.99%
3 Years20.1674.4813.5046.68725,59228.85143.08%
5 Years15.0074.4811.6346.16660,81034.01226.7%

CRISPR Therapeutics Description

CRISPR Therapeutics AG is a gene-editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 is a technology that allows for precise, directed changes to genomic DNA. The company advanced programs target beta-thalassemia and sickle cell disease, two hemoglobinopathies that have a high unmet medical need.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.